2013
Etomidate, Adrenal Function, and Mortality in Critically Ill Patients
Sunshine JE, Deem S, Weiss NS, Yanez ND, Daniel S, Keech K, Brown M, Treggiari MM. Etomidate, Adrenal Function, and Mortality in Critically Ill Patients. Respiratory Care 2013, 58: 639-646. PMID: 22906838, PMCID: PMC4126750, DOI: 10.4187/respcare.01956.Peer-Reviewed Original ResearchConceptsCritical illness-related corticosteroid insufficiencyIll patientsCorticosteroid insufficiencyHospital mortalityAdrenal functionInduction agentAdrenal function testingPrevious randomized studyRole of etomidateRetrospective cohort studyBaseline illness severityRisk of deathAlternative induction agentHigh-risk populationRisk of mortalitySmall randomized trialsAcademic medical centerNumber of deathsEtomidate administrationEtomidate exposureAdjusted riskCohort studySecondary outcomesOverall mortalityPrimary outcome
2003
Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage.
Treggiari MM, Walder B, Suter PM, Romand JA. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. Journal Of Neurosurgery 2003, 98: 978-84. PMID: 12744357, DOI: 10.3171/jns.2003.98.5.0978.Peer-Reviewed Original ResearchConceptsDelayed ischemic neurological deficitsIschemic neurological deficitsHemodilution therapyNeurological deficitsSubarachnoid hemorrhageMethodological qualitySystematic reviewSummary relative risk estimatesRisk of deathMajor end pointsInternal validity scoreRelative risk estimatesStudy methodological qualityRandom-effects modelClinical vasospasmSymptomatic vasospasmCerebral vasospasmRegister searchMAIN OUTCOMEValidity scoresReference listsPaucity of informationVasospasmEnd pointRisk estimates